據報蘋果(AAPL.US)首款混合實境頭盔Vision Pro供應商逾半來自中國
多間媒體引述研究機構維深信息(Wellsenn XR)發布的物料清單,顯示蘋果(AAPL.US)首款混合實境(MR)頭盔Vision Pro的供應商中,逾半來自中國大陸及台灣地區。報告指,來自中國大陸的供應商包括立訊精密、高偉電子(01415.HK)、德賽電池、歌爾、長盈精密、領益製造及兆威機電。
另外,台灣《Digitimes》引述摩根士丹利報告指,台灣地區供應商包括台積電、大立光、業成集團、日月光、和碩、台郡、臻鼎、欣興、景碩、南電及采鈺等。
其他供應商包括三星電子、SK海力士、LG電子、索尼及博通等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.